Table 1.

Characteristics of the pyomelanin-producing isolates of P. aeruginosa and their precursor wild-type isolates.

Pair of isolates	Sequence typea	Source	Isolateb	Production of pyomelanin	Isolation location	Type of infection or colonization	Age of the infection/colonization (days)c	Age of the patient (years)	Antibiotic treatmentd	Reference
PAO1/PAO1 ΔhmgA	ST549	Laboratory	PAO1 PAO1 ΔhmgA	No Yes	–e	–	–	–	–	(Jacobs et al., 2003)
PAO1/CIP	ST549	Laboratory	PAO1 CIP	No Yes	–	–	–	–	Ciprofloxacin	This work
A	ST253	Clinical	Awt Apm	No Yes	Sinus	Sinusitis	10	72	Ceftriaxone, fosfomycin, amikacin	This work
B	ST298	Clinical	Bwt Bpm	No Yes	Blood culture	Urinary sepsis	22	56	Cotrimoxazole	This work
C	ST253	Clinical	Cwt Cpm	No Yes	Tracheal aspirate	Tracheal colonization	36	49	Co-amoxiclav	This work
D	ST974	Clinical	Dwt Dpm	No Yes	Sputum	Pulmonary infection in cystic-fibrosis patient	51	0.8	Colimycin	This work

^aAs determined using the MLST scheme described by Curran et al. (Curran et al., 2004).

^bWT, wild-type; PM, pyomelanin-producing isolate.

^cDuration as first P. aeruginosa isolation.

^dAntibiotic treatment received by the patients before the emergence of pyomelanin-producing isolates.

^eNot applicable.